ArticleJournal of cellular and molecular medicine2025
Integrated Analysis of the LncRNA-Mediated ceRNA Network Associated With Prognosis in Posttreatment Recurrent Nasopharyngeal Carcinoma.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Analysis of the LncRNA-Mediated ceRNA Network Associated With Prognosis in Posttreatment Recurrent Nasopharyngeal Carcinoma.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The competing endogenous RNA hypothesis offers new insights into tumour progression, yet its role in posttreatment nasopharyngeal carcinoma relapse remains unclear. This study constructed ceRNA networks to identify molecular markers associated with NPC relapse. Three pairs of primary and relapse NPC tissue samples, along with their matched adjacent tissues, were collected for the RNA and miRNA sequencing, screened and identified relapse-related specific differentially expressed genes. We identified relapse-specific differentially expressed genes and functional analyses revealed enrichment in translation, biosynthesis, metabolism, TCA cycle, cell cycle, p53 signalling and immune pathways. Then these relapse-associated differentially expressed mRNAs, lncRNAs, and miRNAs were utilised to construct regulatory networks, resulting in a ceRNA network comprising 813 mRNAs, 143 lncRNAs, and 24 miRNAs, along with a survival-associated subnetwork of 23 mRNAs. Key mRNAs, such as UBC, PLA2R1, PTPRO, SMC5, PFN2, TIMM17B, NT5E and PCSK5, were validated via qPCR in NPC cell lines and tissues. To our knowledge, this is the first study to construct a comprehensive ceRNA network specifically for posttreatment recurrent NPC. These findings highlight the ceRNA network as a valuable framework for elucidating the mechanisms of NPC relapse and for identifying potential biomarkers for prognosis and therapeutic targets in recurrent nasopharyngeal carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.